LTA4H

leukotriene A4 hydrolase, the group of M1 metallopeptidases

Basic information

Region (hg38): 12:96000753-96043520

Links

ENSG00000111144NCBI:4048OMIM:151570HGNC:6710Uniprot:P09960AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

No genCC data.

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the LTA4H gene.

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the LTA4H gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
2
clinvar
2
clinvar
4
missense
20
clinvar
2
clinvar
1
clinvar
23
nonsense
0
start loss
0
frameshift
0
inframe indel
0
splice donor/acceptor (+/-2bp)
0
splice region
0
non coding
1
clinvar
1
Total 0 0 20 4 4

Variants in LTA4H

This is a list of pathogenic ClinVar variants found in the LTA4H region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
12-96001014-A-G not specified Uncertain significance (Nov 10, 2022)2350581
12-96001015-C-A not specified Uncertain significance (Jan 10, 2023)2458890
12-96001062-G-C not specified Uncertain significance (Dec 22, 2023)3121374
12-96001065-C-T not specified Uncertain significance (Sep 16, 2021)2353607
12-96001105-C-A not specified Uncertain significance (Mar 28, 2024)3292187
12-96003014-G-A not specified Uncertain significance (Jan 23, 2024)3121373
12-96006381-T-C not specified Likely benign (Oct 12, 2021)2394190
12-96006401-T-A Benign (Jul 31, 2018)718094
12-96006403-C-T not specified Uncertain significance (Mar 28, 2023)2530434
12-96006408-G-A not specified Uncertain significance (Aug 16, 2021)2245506
12-96006409-C-T not specified Uncertain significance (Jul 12, 2023)2610895
12-96013217-G-A Benign (Dec 31, 2019)786610
12-96013781-T-C not specified Uncertain significance (Apr 19, 2023)2538903
12-96013817-T-G not specified Uncertain significance (Dec 06, 2022)2369123
12-96014866-A-T not specified Uncertain significance (Feb 05, 2024)3121372
12-96014959-A-G not specified Uncertain significance (Oct 25, 2022)2318771
12-96014963-G-C not specified Uncertain significance (Jul 15, 2021)2352185
12-96014985-C-T Benign/Likely benign (Apr 01, 2022)786932
12-96015652-G-A Likely benign (Apr 01, 2022)2643223
12-96018811-A-G Benign (Jun 18, 2018)790122
12-96018819-A-C not specified Uncertain significance (Dec 15, 2021)2267483
12-96019211-G-C not specified Uncertain significance (Dec 28, 2022)2340675
12-96022208-C-T not specified Uncertain significance (May 30, 2023)2516306
12-96024492-G-T not specified Uncertain significance (Jun 07, 2024)3292189
12-96027509-G-A not specified Uncertain significance (Apr 25, 2022)2286070

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
LTA4Hprotein_codingprotein_codingENST00000228740 1942693
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
2.96e-80.9991256820661257480.000262
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.482423160.7660.00001513975
Missense in Polyphen85108.190.785651375
Synonymous1.59921140.8100.000005681144
Loss of Function2.961939.00.4870.00000192466

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0005170.000512
Ashkenazi Jewish0.000.00
East Asian0.0001630.000163
Finnish0.0003240.000323
European (Non-Finnish)0.0003160.000308
Middle Eastern0.0001630.000163
South Asian0.0001710.000163
Other0.0006690.000652

dbNSFP

Source: dbNSFP

Function
FUNCTION: Epoxide hydrolase that catalyzes the final step in the biosynthesis of the proinflammatory mediator leukotriene B4. Has also aminopeptidase activity. {ECO:0000269|PubMed:11917124, ECO:0000269|PubMed:12207002, ECO:0000269|PubMed:15078870, ECO:0000269|PubMed:18804029, ECO:0000269|PubMed:1897988, ECO:0000269|PubMed:1975494, ECO:0000269|PubMed:2244921}.;
Pathway
Arachidonic acid metabolism - Homo sapiens (human);Leukotriene modifiers pathway, Pharmacodynamics;Etodolac Action Pathway;Ketoprofen Action Pathway;Ibuprofen Action Pathway;Rofecoxib Action Pathway;Acetylsalicylic Acid Action Pathway;Diflunisal Action Pathway;Leukotriene C4 Synthesis Deficiency;Acetaminophen Action Pathway;Celecoxib Action Pathway;Sulindac Action Pathway;Diclofenac Action Pathway;Ketorolac Action Pathway;Naproxen Action Pathway;Etoricoxib Action Pathway;Carprofen Action Pathway;Flurbiprofen Action Pathway;Fenoprofen Action Pathway;Antrafenine Action Pathway;Antipyrine Action Pathway;Lumiracoxib Action Pathway;Magnesium salicylate Action Pathway;Trisalicylate-choline Action Pathway;Nepafenac Action Pathway;Phenylbutazone Action Pathway;Lornoxicam Action Pathway;Salsalate Action Pathway;Tenoxicam Action Pathway;Tiaprofenic Acid Action Pathway;Tolmetin Action Pathway;Salicylic Acid Action Pathway;Salicylate-sodium Action Pathway;Oxaprozin Action Pathway;Valdecoxib Action Pathway;Nabumetone Action Pathway;Indomethacin Action Pathway;Meloxicam Action Pathway;Suprofen Action Pathway;Bromfenac Action Pathway;Mefenamic Acid Action Pathway;Arachidonic Acid Metabolism;Piroxicam Action Pathway;Eicosanoid Synthesis;Neutrophil degranulation;Metabolism of lipids;Prostaglandin Leukotriene metabolism;Synthesis of Leukotrienes (LT) and Eoxins (EX);Arachidonic acid metabolism;Innate Immune System;Immune System;Metabolism;Biosynthesis of E-series 18(S)-resolvins;Biosynthesis of E-series 18(R)-resolvins;Biosynthesis of EPA-derived SPMs;Biosynthesis of D-series resolvins;Biosynthesis of aspirin-triggered D-series resolvins;Biosynthesis of protectins;Biosynthesis of DHA-derived SPMs;Biosynthesis of specialized proresolving mediators (SPMs);Fatty acid metabolism;leukotriene biosynthesis (Consensus)

Recessive Scores

pRec
0.208

Intolerance Scores

loftool
0.814
rvis_EVS
0.02
rvis_percentile_EVS
55.45

Haploinsufficiency Scores

pHI
0.120
hipred
N
hipred_score
0.492
ghis
0.486

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.999

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Lta4h
Phenotype
immune system phenotype;

Zebrafish Information Network

Gene name
lta4h
Affected structure
epiboly involved in gastrulation with mouth forming second
Phenotype tag
abnormal
Phenotype quality
delayed

Gene ontology

Biological process
proteolysis;leukotriene metabolic process;leukotriene biosynthetic process;long-chain fatty acid biosynthetic process;peptide catabolic process;neutrophil degranulation;cellular lipid metabolic process;cellular protein metabolic process
Cellular component
extracellular region;nucleus;nucleoplasm;cytosol;extracellular exosome;tertiary granule lumen;ficolin-1-rich granule lumen
Molecular function
RNA binding;aminopeptidase activity;epoxide hydrolase activity;leukotriene-A4 hydrolase activity;protein binding;peptidase activity;zinc ion binding;metalloaminopeptidase activity